Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which PICC insertion method causes fewest complications?

NCT ID NCT07791719

Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Aug 28, 2026

Summary

This trial compares three methods of inserting a PICC line, a long tube used to deliver medication, in cancer patients who need one for the first time. Researchers will randomly assign 801 patients across 11 hospitals to receive one of the three insertion techniques. The main goal is to see which method leads to fewer complications, such as infection, bleeding, or the tube moving out of place, within 90 days. The study also looks at pain during insertion and how often the first attempt succeeds.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Three PICC catheter insertion methods: conventional non-tunneled, one-needle tunneled, and two-needle tunneled
What this could lead to
If one method proves safer, it could reduce complications like infection and clotting for cancer patients needing IV therapy.
What could go wrong
The trial is early and results may not apply to all patients. Complications can still occur with any method.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 801 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 75 years * Education level of primary school or above, with adequate reading, writing and --communication skills to independently complete the questionnaire * First-time PICC insertion using a 4Fr single-lumen solo PICC catheter * Able to attend follow-up visits at the same hospital for catheter maintenance after insertion * Willing to participate in the study and sign the informed consent form and PICC insertion consent form Exclusion Criteria: * Coagulation dysfunction (INR \> 1.5 or PLT \< 25 × 10⁹/L) * Use of anticoagulants (e.g., warfarin, heparin) within 3 days before catheterization * Pregnant or lactating women * BMI \< 18.5 kg/m² * Patients requiring lower extremity PICC insertion * Known or suspected allergy to components of the PICC catheter

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer patients are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer patients

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.